Korea Research Institute of Bioscience and Biotechnology

Korea Research Institute of Chemical Technology

Cj Corporation

Jeil Pharm. Co., Ltd.

Jeong-Hyung Lee

Jung Joon Lee

Young-Soo Hong

Young Ho Kim

Sung Soo Kim

Sang Dal Rhee

Won Hoon Jung

Hyae Gyeong Cheon

Sung-eun Yoo

Seung Jun Kim

Seung Kyu Kang

Kwang-Rok Kim

Jae Mok Lee

Jin Hee Ahn

Jong Min Kim

Young Soo Hong

Sung Dae Park

Hang Sub Kim

Hang-Sub Kim

Yun Joo Park

Sung-Don Yang

Nam Gee Kim

Kyeong Seok Lee

Young Deuk Choi

Seog Beom Song

Soon Ji Kwon

Sun Chul Huh

Sun Mee Kim

Koun Ho Lee

B K Shanthaveerappa

Jang Hyuk Lee

Jeong Bum Nam

Yinlan Jin

Dong Hwan Shon

Hye Jung Kang

Jin Hwan Kim

Jung-Joon Lee

Xuejun Jin

Bang-Yeon Hwang

Kil Woong Mo

Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.

Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component

The inventive indene derivatives of formula (I) are capable of selectively modulating the activities of peroxisome proliferator activated receptors (PPARs), causing no adverse side effects, and thus, they are useful for the treatment and prevention of disorders modulated by PPARs, i.e., metabolic syndromes such as diabetes, obesity, arteriosclerosis, hyperlipidemia, hyperinsulinism and hypertension, inflammatory diseases such as osteoporosis, liver cirrhosis and asthma, and cancer.

Indene derivatives and process for the preparation thereof

An indene derivative for selectively modulating the activities of peroxisome proliferator activated receptors (PPARs) having the following formula (I): wherein, or phenyl; being each unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, CN, NH, NO, OR, phenyloxy, Calkyl, and Ccycloalkyl; and

The present invention relates to an alcohol extract of ogalpi, erectile dysfunction improving health food and a treating agent containing the same, more precisely, an alcohol extract of ogalpi having an effect of improving erectile dysfunction, erectile dysfunction improving health food and an erectile dysfunction treating agent containing the same. The alcohol extract of ogalpi of the present invention has a promoting effect of penile erectility, so that it can be effectively used for the improvement of erectile dysfunction.

Method for treating erectile dysfunction with acantopanax extract (ogalpi)

The disclosure concerns an extract ofand its use. More particularly, it concerns the extract ofcomprising 1) the extract ofextracted from water, 2) among the water extract, the extract ofonly containing ethanol insoluble part obtained by precipitating ethanol, 3) among the ethanol insoluble part, the extract ofcontaining polysaccaride with a molecular weight larger than range of 12,000&#x2dc;14,000, or 4) among the ethanol insoluble part, the extract ofcontaining polysaccaride with a molecular weight larger than 100,000, which is respectively obtained from the root or stem ofThe extract of the present invention shows a high inhibitory activity against hepatitis and protects the liver, and thus, can be used for the treatment or prevention of hepatitis, or as a liver protective drug.

[object Object]

The disclosure concerns novel use of diterpene compound as a therapeutic agent of inlfammation, immune disease or cancer. More particularly, the present invention relates to novel use of diterpene compound that include kamebanin, kamebacetal A, kamebakaurin, and exisanin A, which would be effective for the treatment inflammation, immune disease or cancer by inhibiting the production of nitric oxide, prostaglandin, and TNF-through the suppression of NF-B activity.

Use of diterpene compound as a therapeutic agent of inflammation, immune disease or cancer

Disclosed are a novel compound represented by the following chemical formula (1), useful for the prophylaxis and treatment of angiogenic diseases, its production, and a novel microorganism producing the same. Aspergillus sp. Y80118 isolated from soil was found to produce 7,8-dihydro-1,7-dihydroxy-3-hydroxymethyl-xanthenone-8-carboxylic acid methylester which inhibits VEGF-induced proliferation of HUVEC, angiogenesis in CAM assay, and tumor growth. The novel compound can be effectively used for the medical treatment of anigiogenic diseases, including cancers, rheumatoid arthritis, and diabetic retinopathy.

7,8-dihydro-xanthenone-8-carboxylic acid derivative and novel microbe producing the same

The present invention relates to novel isocoumarin derivatves inhibiting angiogenesis, a method for preparation thereof and pharmaceutical compositions comprising the said derivatives as pharmaceutically active ingredients. More particularly, the present invention relates to novel isocoumarin derivatves represented by formula (1), especially 6,8-dihydroxy-4-acetyl-isocoumarin, a method for preparing 6,8-dihydroxy-4-acetyl-isocoumarin from fungi, and pharmaceutical compositions comprising the compounds and/or 6,8-dihydroxy-4-acetyl-isocoumarin as pharmaceutically active ingredients, which would be effective for the treatment of angiogenic diseases such as cancers, rheumatoid arthritis and diabetic retinopathy.

Isocoumarin derivatives inhibiting angiogenesis

Growing community of inventors

Taejeon-si, South Korea

Jeong-Hyung Lee